Sanofi Loses Injunction Bid In Generic Eloxatin Spat

Law360, New York (March 10, 2010, 7:12 PM EST) -- A federal judge has again denied Sanofi-Aventis US LLC's request for a preliminary injunction against Fresenius Kabi Pharma Ltd., one of the last remaining defendants in the pharmaceutical giant's battle to keep generic versions of popular colon cancer drug Eloxatin off the market.

Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Tuesday rejected Sanofi's renewed motion for an injunction against Fresenius without expanding on his reasons.

At Tuesday's hearing, the judge said only that he didn't think Sanofi had...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.